Skip to main content
Premium Trial:

Request an Annual Quote

New Swiss Vaccine Research Institute to Use EPFL's Omics Technologies

NEW YORK (GenomeWeb News) - The Swiss Institute for Vaccine Research, scheduled to open today, will use genomics, proteomics, molecular screening, and imaging technologies provided by the Ecole Polytechnique Fédérale de Lausanne.
 
EPFL will use these technologies to study virology, microbiology, and vectorology and develop new high-flow and automated immunology tests.
 
The primary goal of the SIVR is to develop an immunology, microbiology, and vaccine research laboratory platform intended to encourage collaborative research in the fields of HIV, malaria, tuberculosis, and cancer vaccine development.
 
Other institutes involved in the SIVR include the Centre Hospitalier Universitaire Vaudois, the Faculty of Biology and Medicine at the University of Lausanne, the Institute for Biomedical Research in Bellinzona, and the Ludwig Institute for Cancer Research.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.